Swiss BioTech Platform NUCLIDIUM Secures €84 Million In Series B Round

The round was led by Kurma Growth Opportunities Fund, Angelini Ventures, Wellington Partners, and Neva SGR (Intesa Sanpaolo Group), with support from DTCF, Bayern Kapital, Vives Partners, Eurazeo, NRW.BANK, HighLight Capital, and existing investors.

“NUCLIDIUM is entering the next clinical phases with its lead compounds to diagnose and treat metastatic prostate, neuroendocrine tumors and breast cancer,” said Leila Jaafar, PhD, CEO and Co-Founder of NUCLIDIUM. “Our copper-based radiotheranostics are developed for seamless use in hospital workflows, care delivery and waste management, making these therapies more accessible worldwide. Our groundbreaking next generation copper theranostic platform also allows us to rapidly develop new targets across a wider range of cancers, particularly those highly relevant to women’s health.”

Founded in 2017, NUCLIDIUM AG is a clinical-stage biotech company developing next-gen copper-based radiopharmaceuticals to diagnose and treat cancer.

Read Also - Flyer One Ventures Starts €50M Fund to Support Startups in Ukraine and Central Eastern Europe

By using Copper-61 for imaging and Copper-67 for therapy, NUCLIDIUM is building a unique platform aimed at solving current challenges in radiotheranostics, like limited clinical effectiveness and complex production.

The company is focused on expanding access to more effective cancer care, with a particular emphasis on oncology and women’s health.

“VIVES Partners is thrilled to be among the contributors in this significant fundraising round,” said Sandra Schoors partner at VIVES Partners. “We have a strong belief in the potential of Nuclidium’s copper-based platform as a novel radiotheranostic. The company innovative approach tackles the critical limitations in current radiopharmaceutical methods paving the way for more effective and accessible cancer treatments. We are excited to support this groundbreaking technology and look forward to its transformative impact on healthcare.”

Early clinical trial results show that NUCLIDIUM’s copper-based tracers offer better lesion detection and higher tumor-to-background ratios than currently approved options. Dr. Gary Ulaner presented these findings at SNMMI 2025, noting the favorable safety and imaging performance of 61Cu-NuriPro™.

Initial therapeutic data from lead compounds NuriPro™ and TraceNET™ also show promising results in treating metastatic prostate cancer and neuroendocrine tumors, including breast cancer.

“This significant Series B financing reflects the confidence of our investors in NUCLIDIUM’s vision and the transformative potential for the diagnostic and therapeutic industry in oncology and nuclear medicine” said Tony Rosenberg, Chairman of the NUCLIDIUM Board. “With this backing, we are positioned to accelerate clinical development broaden patient access globally and reinforce our commitment to innovation in precision oncology. I am delighted to welcome our new Board and advisory members whose deep expertise will further strengthen NUCLIDIUM’s leadership in radiopharmaceuticals.”

With this funding, NUCLIDIUM plans to expand its global production network for both diagnostics and therapeutics, grow its international team, and strengthen partnerships with hospitals and academic institutions, starting in Europe and North America.

The investment will also support the clinical development of NUCLIDIUM’s 61Cu/67Cu theranostic pipeline across various cancer types.

As part of the round, Daniel Parera (Kurma Partners), Regina Hodits (Angelini Ventures), and Liliana Nordbakk (Neva SGR) will join NUCLIDIUM’s Board of Directors.

“NUCLIDIUM’s platform stands out in a rapidly evolving field and will change how radiotheranostic care is delivered. This investment reflects our strong conviction in the future of precision medicine and our belief in NUCLIDIUM’s potential to scale as a next-generation company – an ambition shared across a strong European syndicate,” added Daniel Parera, MD, Partner at Kurma Partners, Regina Hodits, PhD, Managing Director at Angelini Ventures, and Liliana Nordbakk, Partner Life Sciences at Neva SGR for all participating investors.

About NUCLIDIUM

Founded in 2017 Nuclidium is transforming precision oncology with its copper-based radiopharmaceuticals for accurate cancer diagnosis and treatment. Its CuTrace™ platform links copper isotopes to targeted molecules, offering safer, more effective solutions. The approach improves hospital access, reduces costs, and streamlines the path from diagnosis to therapy.